Videos

Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.

Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.

Vega discussed recent efforts in the public health field and his own center that have helped to improve screening rates.

Tailor discusses the future of AI in ophthalmology and beyond, and some of the challenges it may bring.

Laine gave an overview of the ACP Internal Medicine’s Friday Plenary session and how it reflects top-of-mind topics for IM clinicians.

Herzig outlined a talk she gave at the ACP Internal Medicine 2025 meeting reviewing the latest data in acute inpatient pain management.

Deepak Bhatt, MD, MPH, MBA, explores high-impact trials from ACC.25, including REVERSE-IT, Alpaca, ADVANCE-HTN, SOUL, STRIDE, and DapaTAVI.

In this episode, hosts break down the STRIDE and SOUL trials presented at the American College of Cardiology 2025 Annual Scientific Sessions.

Gelles discussed AI tools that are becoming a part of clinician’s armamentariums and the impact they are having on the field.

Peter Lio, MD, discusses the value of hyperfocused meetings such as RAD and what sessions he is most looking forward to at RAD 2025.

Goenawan discussed a meta-analysis he presented at the ACP Internal Medicine 2025 meeting.

Winfrey discussed how noninvasive CRC screening tests can help meet gaps when patients face barriers to colonoscopy.

This episode of the SOCS podcast features an in-depth discussion between Crystal Aguh, MD, and John Harris, MD, PhD.

Erickson discussed key health policy issues the ACP is pushing back against during the organization’s Internal Medicine meeting.

Noor discussed the development of an AI model and app trained with a novel saturation strategy to help diagnose mpox.

Lam discussed a retrospective cohort analysis he presented at the 2025 ACP IM meeting and its findings.

Louis discussed the ASKmeGOC study and an electronic tool to help facilitate patient preference documentation.

While the final treatment decision is with the physician, AI may have a role in assisting decision making in virtual urgent care.

In a new analysis at ACC.25, abelacimab reduced bleeding rates across the risk spectrum, with more benefits for those at higher bleeding risk.

Poon discussed a community health needs survey and how the “model minority” myth can impact care for Asian Americans.

Blieden discusses long-term patient management in glaucoma, the importance of follow-up care, and the role of advocacy in ophthalmology.

Blieden describes recent advancements in the detection and treatment of narrow-angle glaucoma at TOA 2025.

Le examines the STRIDE, SOUL, and DapaTAVI trials presented at this year’s ACC Scientific Sessions.

Ahmad Masri, MD, MS, discusses how new options change the historic approach to the treatment of newly diagnosed ATTR-CM.

Daniel Judge, MD, discusses data from a prespecified analysis of ATTRibute-CM examining the effects of acoramidis with and without concomitant tafamidis use.

Ahmad Masri, MD, MS, discusses data detailing the effects of aficamten in oHCM from the FOREST-HCM OLE study at ACC.25.

Our Q1 2025 recap for endocrinology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in diabetes care.

Vallerie Mclaughlin, MD, discusses the ZENITH trial and its historic effects of sotatercept on mortality, transplant risk, and more in PAH.